Xilio Therapeutics Q3 EPS $(0.30) Beats $(0.82) Estimate, Sales $9.984M Beat $4.840M Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.82) by 63.41 percent. This is a 81.01 percent increase over losses of $(1.58) per share
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.82) by 63.41 percent. This is a 81.01 percent increase over losses of $(1.58) per share from the same period last year. The company reported quarterly sales of $9.984 million which beat the analyst consensus estimate of $4.840 million by 106.28 percent. This is a 47.63 percent decrease over sales of $19.066 million the same period last year.